2H-[1,3]氧杂联氮基[3,2-a]吲哚-10-甲酰胺,3,4-二氢-N-[[1-(苯基甲基)-4-哌啶基]甲基]- | 152811-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2H-[1,3]氧杂联氮基[3,2-a]吲哚-10-甲酰胺,3,4-二氢-N-[[1-(苯基甲基)-4-哌啶基]甲基]-
• 英文名称: 3,4-dihydro-N-[1-(phenylmethoxy)-4-piperidinylmethyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide
• 英文别名: N-[(1-Benzyl-4-piperidinyl)methyl]3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide；3,4-dihydro-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide；N-[(1-Benzyl-4-piperidyl)methy] 3,4-dihydro-2 H-[1,3]oxazino[3,2-a]indole-10-Carboxamide；N-[(1-benzylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide
• CAS: 152811-86-4
• 化学式: C₂₅H₂₉N₃O₂
• 分子量: 403.524
• InChiKey: VHHOSEVGENQMGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2H-[1,3]氧杂联氮基[3,2-a]吲哚-10-甲酰胺,3,4-二氢-N-[[1-(苯基甲基)-4-哌啶基]甲基]- 在 palladium 10% on activated carbon 肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以97.3%的产率得到N-(4-piperidinylmethyl)-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide
  参考文献：
  名称：

  WO2007/7072

  摘要：

  公开号：
• 作为产物：
  描述：

  1-苄基哌啶-4-甲胺 、 methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 以 甲苯 为溶剂， 反应 5.0h， 以53.4%的产率得到2H-[1,3]氧杂联氮基[3,2-a]吲哚-10-甲酰胺,3,4-二氢-N-[[1-(苯基甲基)-4-哌啶基]甲基]-
  参考文献：
  名称：

  [EN] MODULATORS OF PERIPHERAL 5-HT RECEPTORS
  [FR] MODULATEURS DE RECEPTEURS PERIPHERIQUES 5-HT

  摘要：

  公开号：

  WO2005061483A3

文献信息

• Piperidine derivatives as 5-HT.sub.4 receptor antagonists
  申请人：SmithKline Beecham plc.

  公开号：US05705498A1

  公开（公告）日：1998-01-06

  Compounds of formula (I): ##STR1## wherein X.sup.g is O, S, SO, SO.sub.2, CH.sub.2, CH, N or NR wherein R is hydrogen or C.sub.1-6 alkyl; A is a saturated or unsaturated polymethylene chain of 2-4 carbon atoms; R.sub.1.sup.g and R.sub.2.sup.g are hydrogen or C.sub.1-6 alkyl; R.sub.3.sup.g is hydrogen, halo, C.sub.1-6 alkyl, amino, nitro or C.sub.1-6 alkoxy; R.sub.4.sup.g is hydrogen, halo, C.sub.1-6 alkyl or C.sub.1-6 alkoxy, Y is O or NH, or CO--Y together are a heterocyclic bioisostere; Z is of sub-formula: ##STR2## wherein --(CH.sub.2).sub.n.sup.1 is attached at carbon; and n.sup.1 is 0, 1, 2, 3 or 4; q is 0, 1, 2 or 3; R.sub.a is a straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by R.sub.7 wherein R.sub.7 is 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, or R.sub.7 is C.sub.2-7 alkoxycarbonyl or secondary or tertiary hydroxy substituted C.sub.1-6 alkyl; and R.sub.6 is hydrogen or C.sub.1-6 alkyl; are useful as 5HT.sub.4 receptor antagonists.

  化合物的式子（I）：##STR1## 其中X.sup.g为O，S，SO，SO.sub.2，CH.sub.2，CH，N或NR，其中R为氢或C.sub.1-6烷基；A为2-4个碳原子的饱和或不饱和聚亚甲基链；R.sub.1.sup.g和R.sub.2.sup.g为氢或C.sub.1-6烷基；R.sub.3.sup.g为氢，卤素，C.sub.1-6烷基，氨基，硝基或C.sub.1-6烷氧基；R.sub.4.sup.g为氢，卤素，C.sub.1-6烷基或C.sub.1-6烷氧基，Y为O或NH，或CO--Y一起是一个杂环生物同位素；Z为亚式式：##STR2## 其中--(CH.sub.2).sub.n.sup.1连接在碳上；n.sup.1为0，1，2，3或4；q为0，1，2或3；R.sub.a为直链或支链烷基，链长为1-6个碳原子，末端被R.sub.7取代，其中R.sub.7为3到8个成员的杂环基，5或6个成员的单环杂环芳基或9或10个成员的融合双环杂环芳基，通过碳连接，或R.sub.7为C.sub.2-7烷氧羰基或次生或三级羟基取代的C.sub.1-6烷基；R.sub.6为氢或C.sub.1-6烷基。它们是5HT.sub.4受体拮抗剂。
• Condensed indole derivatives as 5HT.sub.4 -receptor antagonists
  申请人：SmithKline Beecham plc

  公开号：US05998409A1

  公开（公告）日：1999-12-07

  Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.

  式(I)的化合物及其药学上可接受的盐：##STR1## 以及它们在治疗胃肠道疾病、心血管疾病和中枢神经系统疾病方面的药物应用。
• 5-HTX MODULATORS
  申请人：Klaveness Jo

  公开号：US20090029979A1

  公开（公告）日：2009-01-29

  This invention relates to compounds which bind to serotonin receptors inside or outside the central nervous system, in particular compounds which bind to the 5-HT 2 or 5-HT 7 receptors, their preparation and use, compositions containing them, and methods of treatment using them.

  本发明涉及与中枢神经系统内或外的血清素受体结合的化合物，特别是与5-HT2或5-HT7受体结合的化合物，其制备和使用，包含它们的组合物以及使用它们的治疗方法。
• Modulators of Preripheral 5-Ht Receptors
  申请人：Klaveness Jo

  公开号：US20070254874A1

  公开（公告）日：2007-11-01

  Novel modulators of 5-HT4 receptors have been developed which have a selectivity for peripheral receptors rather than those of the central nervous systems. Theses include novel derivatives of known modulators as well as entirely novel entities. Surprisingly, the derivatised compounds of the known modulators maintain a high binding affinity to 5-HT4 receptors, despite the presence of an acidic moiety at the end of an optional chain. The entirely novel entities also exhibit good binding affinity to 5-HT4 receptors. All of the compounds of the invention have a common motif which includes a basic nitrogen moiety and an acidic moiety. The compounds of the invention, due at least in part to their high ionisation potential at physiological pH, have the unique properties of selectively for peripheral 5HT4 receptors over those of the CNS, good binding affinity, and selectively of 5HT4 receptors over other serotonin receptors.

  已经开发出了5-HT4受体的新型调节剂，其选择性针对的是外周受体而非中枢神经系统受体。其中包括已知调节剂的新型衍生物以及全新的实体。令人惊讶的是，已知调节剂的衍生物化合物尽管在可选链的末端存在酸性基团，但仍保持对5-HT4受体的高结合亲和力。全新的实体也表现出良好的5-HT4受体结合亲和力。发明中的所有化合物都具有一个共同的基团，其中包括一种碱性氮基团和一种酸性基团。该发明中的化合物，至少部分原因是由于它们在生理pH值下具有高离化电位，具有选择性地作用于外周5-HT4受体而非中枢神经系统受体，具有良好的结合亲和力，并且对5-HT4受体的选择性高于其他血清素受体。
• [EN] MODULATORS OF PERIPHERAL 5-HT RECEPTORS<br/>[FR] MODULATEURS DE RECEPTEURS PERIPHERIQUES 5-HT
  申请人：BIO MEDISINSK INNOVASJON AS

  公开号：WO2005061483A3

  公开（公告）日：2005-10-27